Literature DB >> 10952063

Sequence of Abeta-protein deposition in the human medial temporal lobe.

D R Thal1, U Rüb, C Schultz, I Sassin, E Ghebremedhin, K Del Tredici, E Braak, H Braak.   

Abstract

The deposition of Abeta protein (Abeta) and the development of neurofibrillary changes are important histopathological hallmarks of Alzheimer disease (AD). In this study, the medial temporal lobe serves as a model for the changes in the anatomical distribution pattern of different types of Abeta-deposits occurring in the course of AD, as well as for the relationship between the development of Abeta-deposition and that of neurofibrillary pathology. In the first of 4 phases of beta-amyloidosis, diffuse non-neuritic plaques are deposited in the basal temporal neocortex. The same plaque type appears in the second phase within the external entorhinal layers pre-beta and pre-gamma, and fleecy amyloid deposits occur in the internal entorhinal layers pri-alpha, pri-beta, pri-gamma, and in CA1. In the third phase, Abeta-deposits emerge in the molecular layer of the fascia dentata, and band-like Abeta-deposits occur in the subpial portion of the molecular layer of both the entorhinal region and the temporal neocortex. In addition, confluent lake-like Abeta-deposits appear in the parvopyramidal layer of the presubicular region. The fourth phase is characterized by diffuse and core-only plaques in CA4. Diffuse plaques evolve sporadically in the external entorhinal layer pre-alpha. Parallel to the evolution of beta-amyloidosis as represented by the 4 phases, neuritic plaques gradually make their appearance in the temporal neocortex, entorhinal region, CA1, the molecular layer of the fascia dentata, and CA4. A prerequisite for their development is the presence of Abeta and the presence of neurofibrillary tangles in neurons targeting the regions where neuritic plaques evolve. Each of the different types of Abeta-deposits, including neuritic plaques, plays a specific role in the distinct developmental sequence as represented by the 4 phases so that the medial temporal lobe inexorably becomes involved to an ever greater extent. The step-for-step involvement of connected anatomical subfields highlights the importance of the entorhino-hippocampal pathways for the expansion of beta-amyloidosis. The 4 phases in the evolution of beta-amyloidosis correlate significantly with the stages of the neurofibrillary pathology proposed by Braak and Braak.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952063     DOI: 10.1093/jnen/59.8.733

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  111 in total

Review 1.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model.

Authors:  John F Reilly; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

3.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 4.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

5.  A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI.

Authors:  Juan Eugenio Iglesias; Jean C Augustinack; Khoa Nguyen; Christopher M Player; Allison Player; Michelle Wright; Nicole Roy; Matthew P Frosch; Ann C McKee; Lawrence L Wald; Bruce Fischl; Koen Van Leemput
Journal:  Neuroimage       Date:  2015-04-29       Impact factor: 6.556

6.  Whatever happened to Pittsburgh Compound-A?

Authors:  William E Klunk; Chester A Mathis
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

7.  BACE1 retrograde trafficking is uniquely regulated by the cytoplasmic domain of sortilin.

Authors:  Gina M Finan; Hirokazu Okada; Tae-Wan Kim
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

Review 8.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

9.  Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.

Authors:  David S Knopman; Clifford R Jack; Emily S Lundt; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Mary M Machulda; Rosebud O Roberts; Bradley F Boeve; David T Jones; Ronald C Petersen
Journal:  Neurobiol Aging       Date:  2016-06-16       Impact factor: 4.673

10.  Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses.

Authors:  Chi-Cheng Wu; Faisal Chawla; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.